Johnson & Johnson Innovation Archives

News and Trends 19 Oct 2017

Meet some of the Hottest Startups of 2017!

– This article was originally published on 27th September 2017. This is an updated version – Large events, like BIO-Europe offer startup slams, which give entrepreneurs the opportunity to present their company at the conference. Not only does a slam create exposure for the startup, but it also allows young companies to receive valuable feedback from […]

October 19, 2017 - 7 minutesmins - By External Contributor

Apollo Therapeutics drug discovery launch

News and Trends 22 Feb 2017

UK’s Joint Venture Bridging Academia and Industry is Ready for Kick Off

Apollo Therapeutics is a UK-based joint venture bridging academia and industry to drive the translation of university research. Its first four drug discovery programmes will now be launched. Apollo Therapeutics was founded in early 2016 as a collaborative effort of the three global pharmaceutical companies, AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation, and the world-leading UK-universities, Imperial College London, UCL and the University of […]

February 22, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 22 Feb 2017

Meet these 5 Awesome Biotechs from Barcelona at BIO Europe Spring 2017

As BIO Europe Spring 2017 approaches, we decided to take a closer look into biotechs from Barcelona, one of the hottest biotech hubs in Europe. Spring is coming and with it a new edition of BIO Europe Spring that will take place by the beach in Barcelona. The city has established itself as a hub for life sciences within […]

February 22, 2017 - 5 minutesmins - By External Contributor

More News! 9 Feb 2017

After its First Success, the Virtual Biotech Team is Back at it Again

SuperX has raised €10.3M ($11M) in Series A from Medicxi and J&J Innovation to develop anticoagulant antibodies for stroke and heart attacks. The team behind XO1, which was acquired by J&J’s Janssen back in 2015, is repeating the whole process again. Their new company, SuperX, is also focused on the discovery of anticoagulant antibodies to treat […]

February 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2017 01 23 at 3.58.16 PM 1 e1485183691824

News and Trends 23 Jan 2017

New Fundraising Boosts Ultra-Rapid STD Detection

Atlas Genetics has raised €32.6M in Series D. The funds will help the company bring ultra-rapid diagnostic tests for STDs to the market. Atlas Genetics, a spin-off from the University of Bath, has closed an impressive €32.6M ($35M) Series D round of fundraising. The funds will support clinical trials, manufacturing and the commercial launch of the company’s second ultra-rapid […]

January 23, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 15 Jun 2016

Dutch Fund raises €250M to invest in Late Stage Biotechs

Gilde Healthcare has raised €250M for its 4th fund in an oversubscribed round. The money will go to late-stage MedTech, digital health and therapeutics, which can join a portfolio with some of the European celebrity-Biotechs. Gilde Healthcare is based in Utrecht (Netherlands) and Cambridge (Massachussets), investing in healthcare companies on both sides of the Atlantic. This VC […]

June 15, 2016 - 2 minutesmins - By Denise Neves Gameiro

cambridge gsk ucl imperial apollo jj astrazeneca

News and Trends 27 Jan 2016

New UK Joint Venture Bridges Gap between Top Universities and Big Pharmas

AstraZeneca, GlaxoSmithKline, Johnson & Johnson and the 3 world-leading universities (Imperial College London, University College London and the University of Cambridge) have joined forces to found the ‘Apollo’ Bridge. This pioneering new joint venture, the Apollo Therapeutics Fund, will support the translation of ground-breaking academic science from within these universities into innovative new medicines for […]

January 27, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 27 Aug 2015

Dutch Immuno-Oncology company raises Massive Series C Financing round

Sofinnova Ventures and Novo A/S step into one of the biggest European series C financing rounds, which is about €72.8 million. The money goes to the Dutch immuno-oncology company Merus and will advance its cancer-fighting bispecific antibodies. Back in April, Merus announced its intention to go public at the Nasdaq, with the goal of raising […]

August 27, 2015 - 2 minutesmins - By Philip Hemme

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us